Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk

被引:4
|
作者
Winkler, Dirk [1 ]
Schneider, Christof [1 ]
Zucknick, Manuela [2 ]
Boegelein, Daniela [1 ]
Schulze, Kerstin [1 ]
Zenz, Thorsten [1 ]
Mohr, Julia [1 ]
Philippen, Angela [1 ]
Huber, Henriette [1 ]
Buehler, Andreas [1 ]
Habermann, Annett [1 ]
Benner, Axel [2 ]
Doehner, Hartmut [1 ]
Stilgenbauer, Stephan [1 ]
Mertens, Daniel [1 ,2 ]
机构
[1] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[2] DKFZ, Heidelberg, Germany
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷 / 11期
关键词
CLL; protein expression; genetics; prognosis; MANTLE CELL LYMPHOMA; GENOMIC ABERRATIONS; B-CLL; DISTINCT PATHOMECHANISMS; PROGNOSTIC-SIGNIFICANCE; INHIBITOR P27(KIP1); MCL-1; EXPRESSION; DOWN-REGULATION; MUTATION STATUS; IN-VITRO;
D O I
10.3324/haematol.2010.025734
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Chronic lymphocytic leukemia has a variable clinical course. Genomic aberrations identify prognostic subgroups, pointing towards distinct underlying biological mechanisms that are poorly understood. In particular it remains unclear whether the prognostic subgroups of chronic lymphocytic leukemia are characterized by different levels of leukemogenic proteins. Design and Methods Expression of 23 proteins involved in apoptosis, proliferation, DNA damage, and signaling or whose genes map to chromosomal regions known to be critical in chronic lymphocytic leukemia was quantified in 185 cytogenetically well characterized cases of chronic lymphocytic leukemia using immunoblotting. Cases were categorized hierarchically into deletion(17p), deletion(11q), trisomy 12, deletion(13q) as sole abnormality or normal karyotype. Statistical analysis was performed for expression differences between these subgroups. In addition, the expression levels of CDK4, P27 and P53 were quantified over the clinical course and compared to levels in immunopurified B cells from healthy individuals. Results In subgroups with a good prognosis, differential expression was mainly seen for proteins that regulate apoptosis. In contrast, in cytogenetic subgroups with a worse prognosis, differential expression was mostly detected for proteins that control DNA damage and proliferation. Expression levels of CDK4, P27 and P53 were higher compared to those in B cells from healthy individuals and significantly correlated with increasing hierarchical risk. In addition, no significant longitudinal changes of expression levels of CDK4, P27 and P53 could be detected in chronic lymphocytic leukemia patients. Conclusions Differences in expression levels of apoptosis- and proliferation-controlling proteins define distinct prognostic subgroups of chronic lymphocytic leukemia and uncover a correlation of levels of CDK4, P27 and P53 proteins with higher hierarchical risk.
引用
收藏
页码:1880 / 1888
页数:9
相关论文
共 25 条
  • [21] High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle
    Caraballo, Juan M.
    Acosta, Juan C.
    Cortes, Miguel A.
    Albajar, Marta
    Teresa Gomez-Casares, M.
    Batlle-Lopez, Ana
    Angeles Cuadrado, M.
    Onaindia, Arantza
    Bretones, Gabriel
    Llorca, Javier
    Piris, Miguel A.
    Colomer, Dolors
    Leon, Javier
    ONCOTARGET, 2014, 5 (13) : 4694 - 4708
  • [22] Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants
    Fontecha, Maria Belen
    Anadon, Maria Del Rosario
    Guzman, Veronica Mercado
    Stanganelli, Carmen
    Galvano, Camila
    Tosin, Fernanda
    Bordone, Javier
    Bezares, Raimundo
    Rodriguez, Cecilia
    Heller, Viviana
    Slavutsky, Irma
    Fundia, Ariela Freya
    ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5703 - 5712
  • [23] Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors
    Ueki, K
    Nishikawa, R
    Nakazato, Y
    Hirose, T
    Hirato, J
    Funada, N
    Fujimaki, T
    Hojo, S
    Kubo, O
    Ide, T
    Usui, M
    Ochiai, C
    Ito, S
    Takahashi, H
    Mukasa, A
    Asai, A
    Kirino, T
    CLINICAL CANCER RESEARCH, 2002, 8 (01) : 196 - 201
  • [24] Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53
    Christodoulopoulos, G
    Fotouhi, N
    Krajewski, S
    Reed, JC
    AlaouiJamali, M
    Panasci, L
    CANCER LETTERS, 1997, 121 (01) : 59 - 67
  • [25] Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials
    Allan, John N.
    Shanafelt, Tait
    Wiestner, Adrian
    Moreno, Carol
    O'Brien, Susan M.
    Braggio, Esteban
    Liu, Emily
    Dean, James P.
    Lai, Dominic
    Ahn, Inhye E.
    BLOOD, 2020, 136